mRNA-1345 Vaccine for RSV

This trial tests a new vaccine, mRNA-1345, to evaluate its safety and effectiveness in boosting the immune response against RSV, a virus that causes lung infections. Part A focuses on adults under 60 with conditions such as heart disease, chronic lung disease, or diabetes. Part B targets adults who have undergone a kidney, liver, or lung transplant and are on medication to prevent organ rejection. Individuals who can care for themselves and have one of these conditions might be suitable for the trial. As a Phase 3 trial, this is the final step before FDA approval, offering participants a chance to contribute to a potentially groundbreaking treatment.

The trial does not specify if you need to stop taking your current medications. However, if you are in Part A, you should not have been on chronic immunosuppressants or immune-modifying drugs for more than 14 days within 180 days before starting the trial. If you are in Part B, you should not have had certain treatments like alemtuzumab or rituximab within 2 years before starting the trial.

Research has shown that the mRNA-1345 vaccine is generally well-tolerated by adults aged 18-59. In one study, researchers found no major safety issues, and participants did not report any serious side effects.

The most common reactions were mild, such as soreness at the injection site or temporary fatigue. The vaccine was also found to be as effective as other similar vaccines in boosting the immune system.

Researchers are excited about the mRNA-1345 vaccine for RSV because it uses mRNA technology, a newer approach that has already shown promise in fighting other viruses like COVID-19. Unlike traditional vaccines that often use weakened or inactive parts of the virus, mRNA-1345 instructs cells to produce a protein that triggers an immune response, potentially enhancing effectiveness and safety. Additionally, this vaccine is being tested in both single and dual-dose regimens, offering flexibility that could lead to more tailored protection strategies against RSV.

Research has shown that the mRNA-1345 vaccine could help protect adults from RSV, a virus affecting the lungs. In this trial, participants will receive different dosing regimens of the mRNA-1345 vaccine. One study found that a single dose of this vaccine reduced RSV-related lung infections in older adults. It also maintained a strong immune response for up to six months after administration, with no major safety concerns. Receiving another dose after a year continued to provide good protection. These results suggest that mRNA-1345 could effectively prevent RSV infections in high-risk adults, including those who have had organ transplants.⁴⁶⁷⁸⁹